CD20单抗联合苯达莫司汀治疗惰性淋巴瘤的疗效及安全性  

Efficacy and safety of CD Efficacy and safety of CD20 monoclonal antibody combined with bendamustine in the treatment of inert lymphoma

作　　者：蓝清华 曾庆芳 宋欢 詹涛 钟建明 LAN Qinghua;ZENG Qingfang;SONG Huan;ZHAN Tao;ZHONG Jianming(Third Department of Medical Oncology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Medical Oncology,the People’s Hospital of Yudu County,Ganzhou 342300,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院肿瘤内科三区,江西赣州341000 [2]于都县人民医院肿瘤内科,江西赣州3423000

出　　处：《癌症进展》2023年第12期1302-1305,共4页Oncology Progress

基　　金：赣州市指导性科技计划项目(GZ2018ZSF365)。

摘　　要：目的探讨CD20单抗联合苯达莫司汀治疗惰性淋巴瘤的疗效及安全性。方法根据治疗方式的不同将90例惰性淋巴瘤患者分为对照组(n=44)和观察组(n=46),对照组患者给予化疗,观察组患者在对照组的基础上给予苯达莫司汀联合CD20单抗治疗。比较两组患者临床疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+))及不良反应发生情况。结果观察组患者的疾病控制率为82.61%,高于对照组患者的61.36%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平均高于本组治疗前,CD8^(+)水平均低于本组治疗前,且观察组患者CD3^(+)、CD4^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为76.09%,与对照组患者的77.27%比较,差异无统计学意义(P﹥0.05)。结论CD20单抗联合苯达莫司汀治疗惰性淋巴瘤患者的疗效显著,可提高患者的免疫功能,且不会增加不良反应。Objective To investigate the efficacy and safety of CD20 monoclonal antibody combined with benda-mustine in indolent lymphoma.Method A total of 90 patients with indolent lymphoma were divided into control group(n=44,treated with chemotherapy)and observation group(n=46,treated with chemotherapy combined with bendamus-tine+CD20 monoclonal antibody)according to the treatment methods.The clinical efficacy,immune function indicators(CD3^(+),CD4^(+),CD8^(+))and adverse reactions were compared between the two groups.Result The disease control rate of the observation group patients was 82.61%,higher than 61.36%of the control group,the difference was statistically sig-nificant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in both groups were higher than those before the treat-ment,while the levels of CD8^(+)were lower than those before the treatment,the levels of CD3^(+)and CD4^(+)in the observa-tion group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 76.09%,and there was no statistically significant difference compared to 77.27% in the control group(P>0.05).Conclusion CD20 monoclonal antibody+bendamustine can improve the efficacy and immune function of patients with indo-lent lymphoma without increasing adverse reactions.

关 键 词：惰性淋巴瘤 CD20单抗 苯达莫司汀 安全性 

分 类 号：R733.4[医药卫生—肿瘤]